CompletedNCT04016779
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Researchers compared SPN-812 and placebo, tracking side effects to assess safety in adults with ADHD.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared SPN-812 and placebo, tracking side effects to assess safety in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Garden Grove, United States · Los Alamitos, United States and 33 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: November 20, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 374
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04016779
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedGarden Grove · Los Alamitos · Newport Beach
32 more locations
- Riverside
- San Diego
- San Marcos
- Torrance
- Fort Myers
- Hollywood
- Jacksonville
- Lakeland
- Orange City
- Orlando
- Tampa
- Atlanta
- Decatur
- Marietta
- Overland Park
- Saint Charles
- Lincoln
- Las Vegas
- Berlin
- Cherry Hill
- Marlton
- Princeton
- Mount Kisco
- New York
- Oklahoma City
- Memphis
- Austin
- Dallas
- Houston
- The Woodlands
- Clinton
- Bellevue
Questions about this study
What did researchers investigate?
Researchers compared SPN-812 and placebo, tracking side effects to assess safety in adults with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and SPN-812.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)